Galera Therapeutics, Inc. 8-K

What Happened

• Galera Therapeutics, Inc. filed a Form 8-K (filed July 13, 2026) reporting a one-for-two hundred (1:200) reverse stock split of its common stock, effected by an amendment to its Restated Certificate of Incorporation that became effective at 11:59 p.m. Eastern Time on July 12, 2026. The company’s common stock (par value $0.001) began trading on a split‑adjusted basis on the OTCQB Market under the ticker symbol “GRTXD” when the market opened on July 13, 2026.

Key Details

• Reverse ratio: 1-for-200 (effective July 12, 2026 at 11:59 p.m. ET).
• Trading: Split-adjusted shares began trading on OTCQB as “GRTXD” on July 13, 2026.
• Impact on equity awards: The number of shares available under the company’s 2019 Equity Incentive Plan and 2023 Employment Inducement Award Plan, and shares issuable on outstanding options and warrants, were reduced by the 1:200 ratio; exercise prices for options and warrants were increased proportionately.
• Fractional shares: No fractional post-split shares will be issued. Stockholders entitled to fractional shares will receive a cash payment equal to the fractional amount multiplied by the closing OTCQB price on the last trading day before the split, multiplied by 200.

Why It Matters

• The reverse split reduces the number of outstanding shares and increases the per-share price proportionally. For investors, this changes the share count on holdings, the number of shares subject to stock options and warrants, and the per-share exercise prices (all adjusted by the 1:200 ratio).
• Cash-in-lieu for fractional shares means small fractional holdings will be converted to cash rather than retained as fractional shares. The filing’s amendment to the certificate of incorporation formalizes these changes and is attached as Exhibit 3.1 to the 8-K.